234 related articles for article (PubMed ID: 15291653)
21. Fluvoxamine-clozapine interaction: time-dependent?
Lu ML; Lane HY; Chang WH
J Clin Psychopharmacol; 2002 Aug; 22(4):439-40. PubMed ID: 12172350
[No Abstract] [Full Text] [Related]
22. Body weight gain in clozapine-treated patients: Is norclozapine the culprit?
Jessurun NT; Derijks HJ; van Marum RJ; Jongkind A; Giraud EL; van Puijenbroek EP; Grootens KP
Br J Clin Pharmacol; 2022 Feb; 88(2):853-857. PubMed ID: 34355423
[TBL] [Abstract][Full Text] [Related]
23. Dosing strategies of clozapine-fluvoxamine cotreatment.
Lu ML; Lane HY; Jann MW; Chang WH
J Clin Psychopharmacol; 2002 Dec; 22(6):626-8. PubMed ID: 12454566
[No Abstract] [Full Text] [Related]
24. Hyperglycemia, hyperlipemia, and periodic paralysis: a case report of new side effects of clozapine.
Wu G; Dias P; Chun W; Li G; Kumar S; Singh S
Prog Neuropsychopharmacol Biol Psychiatry; 2000 Nov; 24(8):1395-400. PubMed ID: 11125862
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetic interaction of fluvoxamine and thioridazine in schizophrenic patients.
Carrillo JA; Ramos SI; Herraiz AG; Llerena A; Agundez JA; Berecz R; Duran M; Benítez J
J Clin Psychopharmacol; 1999 Dec; 19(6):494-9. PubMed ID: 10587283
[TBL] [Abstract][Full Text] [Related]
26. The differential effects of steady-state fluvoxamine on the pharmacokinetics of olanzapine and clozapine in healthy volunteers.
Wang CY; Zhang ZJ; Li WB; Zhai YM; Cai ZJ; Weng YZ; Zhu RH; Zhao JP; Zhou HH
J Clin Pharmacol; 2004 Jul; 44(7):785-92. PubMed ID: 15199083
[TBL] [Abstract][Full Text] [Related]
27. Serum levels of clozapine and norclozapine in patients treated with selective serotonin reuptake inhibitors.
Centorrino F; Baldessarini RJ; Frankenburg FR; Kando J; Volpicelli SA; Flood JG
Am J Psychiatry; 1996 Jun; 153(6):820-2. PubMed ID: 8633698
[TBL] [Abstract][Full Text] [Related]
28. Fluvoxamine increases plasma and urinary levels of clozapine and its major metabolites in a time- and dose-dependent manner.
Fabrazzo M; La Pia S; Monteleone P; Mennella R; Esposito G; Pinto A; Maj M
J Clin Psychopharmacol; 2000 Dec; 20(6):708-10. PubMed ID: 11106150
[No Abstract] [Full Text] [Related]
29. Clozapine: diabetes mellitus, weight gain, and lipid abnormalities.
Henderson DC
J Clin Psychiatry; 2001; 62 Suppl 23():39-44. PubMed ID: 11603884
[TBL] [Abstract][Full Text] [Related]
30. Changes in serum lipids, independent of weight, are associated with changes in symptoms during long-term clozapine treatment.
Procyshyn RM; Wasan KM; Thornton AE; Barr AM; Chen EY; Pomarol-Clotet E; Stip E; Williams R; Macewan GW; Birmingham CL; Honer WG;
J Psychiatry Neurosci; 2007 Sep; 32(5):331-8. PubMed ID: 17823649
[TBL] [Abstract][Full Text] [Related]
31. Different influences of classical antipsychotics and clozapine on glucose-insulin homeostasis in patients with schizophrenia or related psychoses.
Melkersson KI; Hulting AL; Brismar KE
J Clin Psychiatry; 1999 Nov; 60(11):783-91. PubMed ID: 10584769
[TBL] [Abstract][Full Text] [Related]
32. Should lipids be monitored during the first year of treatment with an atypical antipsychotic?
Landry P; Benaliouad F
Can J Psychiatry; 2003 Jun; 48(5):348-9. PubMed ID: 12866344
[No Abstract] [Full Text] [Related]
33. Weight gain during a double-blind multidosage clozapine study.
de Leon J; Diaz FJ; Josiassen RC; Cooper TB; Simpson GM
J Clin Psychopharmacol; 2007 Feb; 27(1):22-7. PubMed ID: 17224708
[TBL] [Abstract][Full Text] [Related]
34. Plasma levels of clozapine and norclozapine in Mexican schizophrenia patients.
González-Esquivel DF; Castro N; Ramírez-Bermúdez J; Custodio V; Rojas-Tomé S; Castro-Román R; Jung-Cook H
Arzneimittelforschung; 2011; 61(6):335-9. PubMed ID: 21827043
[TBL] [Abstract][Full Text] [Related]
35. Effect of omega-3 fatty acids on the lipid profile of patients taking clozapine.
Caniato RN; Alvarenga ME; Garcia-Alcaraz MA
Aust N Z J Psychiatry; 2006 Aug; 40(8):691-7. PubMed ID: 16866765
[TBL] [Abstract][Full Text] [Related]
36. Dyslipidemia independent of body mass in antipsychotic-treated patients under real-life conditions.
Birkenaes AB; Birkeland KI; Engh JA; Faerden A; Jonsdottir H; Ringen PA; Friis S; Opjordsmoen S; Andreassen OA
J Clin Psychopharmacol; 2008 Apr; 28(2):132-7. PubMed ID: 18344722
[TBL] [Abstract][Full Text] [Related]
37. Population pharmacokinetics of clozapine and its primary metabolite norclozapine in Chinese patients with schizophrenia.
Li LJ; Shang DW; Li WB; Guo W; Wang XP; Ren YP; Li AN; Fu PX; Ji SM; Lu W; Wang CY
Acta Pharmacol Sin; 2012 Nov; 33(11):1409-16. PubMed ID: 22820910
[TBL] [Abstract][Full Text] [Related]
38. Effect of fluvoxamine augmentation and smoking on clozapine serum concentrations.
Augustin M; Schoretsanitis G; Pfeifer P; Gründer G; Liebe C; Paulzen M
Schizophr Res; 2019 Aug; 210():143-148. PubMed ID: 31182321
[TBL] [Abstract][Full Text] [Related]
39. Fluvoxamine dose-dependent interaction with haloperidol and the effects on negative symptoms in schizophrenia.
Yasui-Furukori N; Kondo T; Mihara K; Inoue Y; Kaneko S
Psychopharmacology (Berl); 2004 Jan; 171(2):223-7. PubMed ID: 12955290
[TBL] [Abstract][Full Text] [Related]
40. Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis.
De Hert M; Yu W; Detraux J; Sweers K; van Winkel R; Correll CU
CNS Drugs; 2012 Sep; 26(9):733-59. PubMed ID: 22900950
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
